# A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

> **NCT03216226** · PHASE3 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 112 (actual)

## Conditions studied

- Hypoglycemia
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** dasiglucagon
- **DRUG:** GlucaGen

## Key facts

- **NCT ID:** NCT03216226
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2018-02-13
- **Final completion:** 2018-02-13
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2021-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216226, "A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03216226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*